Anticholinergic vs. Botox Comparison Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Anticholinergic vs. Botox Comparison Study (NCT01166438), a randomized phase 3 study. The primary outcome is Change in Urge Urinary Incontinence (UUI) Episodes.

2. Clinical Question

3. Trial Design

This was a phase 3, randomized, triple-masked, parallel-group trial. The registry record lists enrollment of 249 and identifies the sponsor as the NICHD Pelvic Floor Disorders Network. The study is marked completed. Its recorded start was 2010-03 and its primary completion was 2012-05.

The parallel design assigned participants to one of two treatment strategies: botulinum toxin A injection with oral placebo tablets, or a standardized oral anticholinergic regimen with saline injection. This setup compares the overall strategies, not the isolated effect of an injection against the isolated effect of a tablet. Each arm includes an active component and a placebo component.

The Botox A arm is described as a single intradetrusor injection of 100U botulinum toxin A plus daily oral placebo tablets. The comparator arm is described as a single intradetrusor saline injection plus daily oral anticholinergic medication. The medication regimen started with solifenacin 5 mg for 2 mo; solifenacin 10mg and trospium chloride XR 60mg are also listed. The detailed decision rules for changing medication are not reported in the registry record.

The trial’s stated observation period for the primary outcome was baseline through 6 months, within a double-blind period. The meaning and operational details of triple masking are not described in the registry record, so the specific roles kept unaware of assignment should not be inferred. Eligibility criteria, recruitment locations, and the statistical plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Double-blind Phase: 1st 6 Months

Reasons for not completing this period:

Off Treatment Follow-up Phase

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Urge Urinary Incontinence (UUI) Episodes, measured over Baseline through 6 months.

The primary endpoint is the change from baseline in the mean number of urge urinary incontinence episodes over the 6-month double-blind period. The measure focuses on episode frequency, rather than on a binary status such as whether a participant experienced any episode. A change score expresses how the measured average shifted from the baseline assessment during follow-up.

Episode frequency is relevant to the stated study question because the trial was designed to compare two treatment strategies for reducing urge urinary incontinence. A group-level mean summarizes the average change across participants, while individual experiences may vary. The endpoint is continuous, and the registry identifies the dispersion measure as the standard error. The unit is described as mean change in UUI episodes from baseline.

The record lists the timeframe as baseline through 6 months and describes the measure as change from baseline in mean episode number over the 6-month double-blind period. It does not report the actual arm-specific changes, the between-arm contrast, or uncertainty estimates for that contrast. The primary outcome has several categories or time points and is not reduced to a single comparison in the posted results. Consequently, the endpoint’s definition is available, but the primary comparative result cannot be interpreted from the registry record alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The record identifies the primary measure as a mean change in a continuous outcome. It also labels the dispersion as standard error. However, the record does not report the primary estimates or a single comparison, and it does not describe the analysis model or the statistical plan. The concepts below explain how such results are generally read; they are not claims about methods used in this trial.

What does a mean change represent?

In general, a mean change is calculated by comparing each participant’s follow-up measure with that participant’s baseline measure, then summarizing those changes across a group. The group mean describes the average direction and size of change in that group. Comparing mean changes between randomized groups can estimate the difference between treatment strategies, provided the analysis and outcome data are appropriately handled.

A mean is a summary, not a description of every participant’s experience. Some participants can have changes above the group average and others below it. The mean may also be influenced by unusually high or low values. The registry record does not report the distribution of individual episode counts, so its shape and variability cannot be assessed from the posted primary outcome information.

What does standard error describe?

In general, a standard error describes the uncertainty in an estimated statistic, such as a group mean. It is not the same as the spread of individual participant measurements. The standard error is useful when considering how precisely a group estimate has been estimated, but a group’s standard error alone does not provide the uncertainty for a between-group contrast. That requires the comparison estimate and its uncertainty, or information sufficient to derive them under appropriate assumptions.

A confidence interval is a general way to express uncertainty around an estimate. It gives a range of values compatible with the data and the method used to construct the interval. A narrow interval indicates more precision than a wide interval, but neither the interval nor the estimate is reported for the primary comparison in this registry record. Statistical significance, if reported, would not by itself describe clinical importance; the size and precision of the contrast would also matter.

Why does the comparison need a defined analysis?

In general, an analysis plan specifies how outcomes are summarized and compared, which participants contribute data, how missing observations are handled, and how any repeated measurements or other features are modeled. Different reasonable choices can affect estimates and uncertainty. The statistical plan and analysis population for this trial are not reported in the registry record, so the analytical choices cannot be assessed.

The primary outcome is described across baseline through 6 months, while the registry notes that it has several categories or time points and is not reduced to a single comparison. Repeated measurements can be analyzed in different ways. General approaches may compare change at a specified follow-up, model measurements over time, or summarize a trajectory. These approaches answer related but not necessarily identical questions. The record does not state which approach was used for the posted outcome information.

What do the planning assumptions mean?

In general, a sample-size calculation is a planning exercise about how much information a future study might need under stated assumptions. The registry’s planning assumptions describe a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is expressed as a stated fraction of an observed effect. Such illustrations depend on their assumptions and are not observed trial results or evidence that a study had a particular probability of detecting an effect.

The assumptions do not establish the trial’s original design rationale. The registry record does not report the trial’s own sample-size justification, the effect size used in its planning, or an interim-analysis plan. Any planning illustration should therefore be read as a hypothetical calculation rather than as proof of the trial’s design process or a measure of its observed performance.

How should multiple outcomes be considered?

In general, testing many outcomes or time points can increase the chance of finding at least one apparently unusual result by chance, unless the analysis addresses multiplicity or makes clear which result is primary. A prespecified primary endpoint helps distinguish the main confirmatory question from other outcomes, but interpretation still depends on the analysis plan and how results are reported. The record lists secondary outcomes but does not describe multiplicity procedures or provide their results.

Because the primary outcome is not reduced to one comparison and the analysis details are not reported, the statistical evidence for the trial’s central question cannot be reconstructed from this record. A complete interpretation would require the relevant estimates, uncertainty, analysis description, and handling of outcome data.

10. Multiplicity, Missing Data and Analysis Populations

The record identifies a primary endpoint and lists secondary outcomes, but does not report the statistical plan for handling multiple outcomes or time points. The primary outcome is noted as having several categories or time points and is not reduced to a single comparison. The registry record therefore does not show which primary contrast, time point, or analysis was used to support a conclusion.

In general, multiplicity arises when several statistical comparisons are considered. Without an analysis plan, readers cannot tell whether secondary findings were treated as exploratory, whether any adjustment was used, or how the primary question was distinguished from other tests. The record does not report multiplicity procedures or secondary outcome results.

The analysis population is not reported in the registry record. In particular, the record does not specify whether the primary analysis included everyone as randomized, only participants with available outcome data, or another defined group. The missing-data approach is also not reported: there is no description of how incomplete episode records, withdrawals, or other unavailable measurements were handled.

These omissions matter because the amount and pattern of missing outcome data can affect an estimate, and different analysis populations can answer different questions. The record also does not describe adherence handling, exclusions from analysis, or sensitivity analyses. These methods cannot be inferred from the randomized design or from the completion status. Without the analysis population, missing-data procedures, and statistical plan, the robustness of any primary or secondary inference cannot be assessed from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: upper respiratory tract infection (0.8%), head injury (0.8%), back pain (0.8%), convulsion (0.8%), haematuria (0.8%).

The registry lists serious adverse events affecting 5 participants in the Botox A group, with 121 at risk, and 7 in the standardized anticholinergic group, with 126 at risk. It separately lists other adverse events affecting 96 and 97 participants, with 121 and 126 at risk, respectively. These are counts as recorded, not estimates of a treatment effect.

In general, an at-risk count indicates the group size used for the adverse-event entry. A count of participants affected is not necessarily the same as a count of individual events, since a participant may experience more than one event. The record does not explain the detailed event-counting rules, follow-up completeness, or statistical comparison for these entries. The counts should therefore be read descriptively.

The serious-event term summary lists upper respiratory tract infection, head injury, back pain, convulsion, haematuria, and cardiac septal hypertrophy, each at 0.8%. The registry summary does not assign these listed terms to a particular arm in the information recorded. Death counts are not reported in the registry record. These entries do not capture all details needed to assess timing, severity beyond the serious classification, relatedness, or comparative risk.

Differences between the listed counts should not be interpreted as evidence of a safety advantage or disadvantage without a defined comparative analysis and fuller context. These safety data also do not answer the primary efficacy question about change in urge urinary incontinence episodes.

12. What the Result Does, and Does Not, Mean

The record shows that a randomized comparison was designed to evaluate a single botulinum toxin A injection strategy against a standardized oral anticholinergic strategy, with change in mean urge urinary incontinence episodes over 6 months as the primary outcome. It also records selected adverse-event counts. These details establish what the study set out to compare and some of the information entered in the registry.

The record does not report a single reduced comparison for the primary outcome. It therefore does not establish which group had a larger mean change, how large any contrast was, or how precisely it was estimated. The absence of a reduced comparison is not evidence that the groups were the same, and it is not evidence that either strategy had an advantage. It means the central comparative result cannot be read from the posted registry information.

The listed secondary outcome names likewise do not indicate their results. Without estimates and uncertainty, it is not possible to determine the size or precision of differences on those measures. The adverse-event counts are descriptive and do not establish comparative safety; the registry record does not report a statistical comparison for them.

In general, a randomized design can support a causal comparison when the assigned groups are analyzed appropriately and outcome data are available, but design labels alone do not provide the result. Interpretation also depends on the analysis population, handling of missing data, and statistical methods. Those details are not reported in the registry record.

Accordingly, the record supports a description of the trial question, design, endpoint definition, and selected safety entries. It does not support a conclusion about efficacy, equivalence, clinical importance, or the comparative balance of benefits and harms. Those conclusions require results and methods that are not reported in the registry record.

13. Why This Trial Matters Statistically

This trial’s statistical question is a comparison of two treatment strategies rather than a simple comparison of a drug with no treatment. The Botox A arm paired an active injection with oral placebo tablets; the anticholinergic arm paired active oral medication with a saline injection. That design makes the stated question relevant to the strategies as delivered, while also making clear that the comparison is not an isolated test of injection versus tablet.

The endpoint is a change in a repeated symptom measure: mean urge urinary incontinence episodes from baseline through 6 months. For this kind of outcome, statistical interpretation depends not only on a group average but also on how measurements over time were collected and analyzed, how much uncertainty surrounds the comparison, and how incomplete data were handled. These methods are not reported in the registry record.

The case also illustrates why a trial’s design and objective should be kept separate from its results. Randomization, masking, and a prespecified primary question describe the intended structure of evidence. They do not reveal the observed treatment contrast. Here, the primary outcome has several categories or time points and is not reduced to a single comparison in the posted results. Without that comparative estimate, the central statistical question remains open in the registry record.

The safety entries provide another useful statistical distinction. Counts of participants affected are descriptive summaries; they are not automatically a formal comparison of risk, and they do not resolve the efficacy question. Clear interpretation requires knowing what was counted, how follow-up was handled, and what comparative analysis was prespecified.

These features matter to clinical researchers because a conclusion depends on the connection between the question, endpoint, analysis, and reported estimate. A completed randomized trial can still be difficult to interpret when key outcome results or analytical details are absent from the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting the treatment comparison is that the primary endpoint is not reduced to a single comparison in the registry results. The record describes the measure and timeframe but does not report the arm-specific means, the between-arm contrast, or uncertainty for that contrast. Consequently, the magnitude and precision of the primary result are not reported in the registry record.

The registry does not report the analysis model, analysis population, missing-data method, or statistical plan. It also does not describe whether or how the analysis accounted for multiple outcome categories or time points. These omissions prevent assessment of whether the posted analysis follows a prespecified approach and whether its conclusions would be robust to alternative reasonable choices.

The standardized anticholinergic regimen is described as a three-step approach, with solifenacin 5 mg at the start and solifenacin 10mg and/or trospium chloride XR 60mg listed. However, the full treatment-change instructions are not reported in the registry record. The exact implementation of the comparator strategy therefore cannot be fully reconstructed from its description.

Specific eligibility criteria, baseline participant characteristics, and details of outcome measurement are not reported in the registry record. The record also does not provide detailed follow-up completeness or the reasons for missing measurements. These gaps limit assessment of the population represented and the quality of outcome ascertainment.

Safety reporting is similarly limited: the record gives selected counts and serious-event terms but does not report a comparative analysis, detailed event timing, or death counts. These limitations do not imply a particular trial result; they define what cannot be determined from the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Anticholinergic vs. Botox Comparison Study — NCT01166438.
• Registry record last updated 2018-05-02; status last verified 2018-04.
• Results first posted 2017-12-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed phase 3, randomized, triple-masked, parallel-group trial sponsored by the NICHD Pelvic Floor Disorders Network, with enrollment of 249. It compared a single intradetrusor injection of 100U botulinum toxin A plus oral placebo tablets with a standardized oral anticholinergic regimen plus a saline injection.

The primary endpoint was change from baseline in mean urge urinary incontinence episodes over the 6-month double-blind period. The registry states that the primary outcome has several categories or time points and is not reduced to one comparison. Arm-specific primary results and a comparative estimate are not reported in the registry record.

Selected serious and other adverse-event counts are listed by group. The record does not report the primary analysis methods, missing-data handling, or analysis population.